Advertisement
Singapore markets closed

  • Straits Times Index

    3,292.93
    -3.96 (-0.12%)
     

  • Nikkei

    38,236.07
    -37.98 (-0.10%)
     

  • Hang Seng

    18,475.92
    +268.79 (+1.48%)
     

  • FTSE 100

    8,205.09
    +32.94 (+0.40%)
     

  • Bitcoin USD

    59,445.70
    +1,734.56 (+3.01%)
     

  • CMC Crypto 200

    1,285.36
    +8.38 (+0.66%)
     

  • S&P 500

    5,064.20
    +45.81 (+0.91%)
     

  • Dow

    38,225.66
    +322.37 (+0.85%)
     

  • Nasdaq

    15,840.96
    +235.48 (+1.51%)
     

  • Gold

    2,310.10
    +0.50 (+0.02%)
     

  • Crude Oil

    79.00
    +0.05 (+0.06%)
     

  • 10-Yr Bond

    4.5710
    -0.0240 (-0.52%)
     

  • FTSE Bursa Malaysia

    1,589.59
    +9.29 (+0.59%)
     

  • Jakarta Composite Index

    7,134.72
    +17.30 (+0.24%)
     

  • PSE Index

    6,615.55
    -31.00 (-0.47%)
     

Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference

Achilles Therapeutics PLC
·1-min read
Achilles Therapeutics PLC
Achilles Therapeutics PLC

LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the Company will be presenting at the following conference:

10th Annual Immuno-Oncology 360 Conference (IO360)
Speaker: Sergio Quezada, PhD, Chief Scientific Officer
Presentation: Targeting Clonal Neoantigens with Precision Cell Therapies
Location: New York Marriott at The Brooklyn Bridge, Brooklyn NY
Date: February 29, 2024
Time: 10:30am ET

For more information about IO360, please visit https://io360summit.com.

ADVERTISEMENT

About Achilles Therapeutics

Achilles is a clinical-stage biopharmaceutical company developing AI-Powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

Investors:
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com

Media:
ICR Consilium
Sukaina Virji, Tracy Cheung, Emmalee Hoppe
+44 (0) 203 709 5000
achillestx@consilium-comms.com